Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drug developer Arena Pharmaceuticals
So what: This morning, Arena issued a press release revealing the data analysis that the company presented at the European Congress on Obesity. Specifically, the company showed that in its phase 3 clinical trial program, subjects taking its lorcaserin drug were more likely to lose weight than those on a placebo. The company also noted that adverse reactions were relatively mild.
Now what: While the data analysis is interesting, investors still have to face the nagging question of whether the Food and Drug Administration will actually approve the drug. Back in October, the FDA turned the drug down due to concerns over efficacy and cancer risk. Does today's news change that picture? The Associated Press quoted Lazard analyst William Tanner, who says it doesn't and that the prospects for approval still look dim.
Want to keep up to date on Arena Pharmaceutical? Add it to your watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer does not have a financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or Facebook. The Fool’s disclosure policy prefers dividends over a sharp stick in the eye.